Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861940 | 0.85 | HRH3 (0.38) | GNAI3GNAO1GNAI1KDM1AKDM4E | |
| SCHEMBL25827075 | 0.85 | GNAI3 (0.43) | GNAI3GNAO1GNAI1KDM4EHRH3 | |
| SCHEMBL21107904 | 0.84 | KDM4E (0.33) | GNAI3GNAO1GNAI1KDM1AKDM4E | |
| SCHEMBL22837671 | 0.82 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3KDM1AKDM4E | |
| SCHEMBL25831692 | 0.82 | GNAI3 (0.35) | GNAI3GNAO1GNAI1KDM1AKDM4E | |
| SCHEMBL23695901 | 0.82 | KDM1A (0.32) | GNAI3GNAO1GNAI1KDM1AKDM4E | |
| SCHEMBL23986335 | 0.81 | CARM1 (0.36) | GNAI3GNAO1GNAI1 | |
| SCHEMBL23568551 | 0.81 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3GNAI3GNAO1 | |
| SCHEMBL26018288 | 0.80 | GNAI3 (0.34) | SLC6A2SLC6A4SLC6A3GNAI3GNAO1 | |
| SCHEMBL25477755 | 0.79 | PRMT6 (0.37) | SLC6A2SLC6A4SLC6A3GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.